April 7 Practice & Trends On The Cover Health care teams for gender-affirming care have a clear place for pharmacists PT April 2024 Hormone therapy, specifically estradiol and testosterone, are familiar drugs. Pharmacists know how they interact with other medications. What is less clear is how pharmacists fit into the changing landscape of clinics and health care teams as transgender individuals seek gender-affirming hormone therapy, a medical intervention to align appearance with gender identity. Loren Bonner & Clarissa Chan, PharmD
April 7 Practice & Trends On The Docket A system failure leads to late medication delivery and patient death PT April 2024 Hospitals can be held liable for causing harm to patients either due to the negligence of employed health care professionals (indirect liability) or for institutional negligence (direct liability). David B. Brushwood, BSPharm, JD
April 7 Practice & Trends Pharmacy Closures Pharmacists stuck between legal rock and contractual hard place PT April 2024 Pharmacies are struggling—both the independents and the chains. The ACT Pharmacy Collaborative, a partnership with CPESN and pharmacy academia, reported closures of 244 pharmacies including independents and chains in 48 states in just the first 6 weeks of 2024. Sonya Collins
April 7 Practice & Trends Birth Control Pharmacies expand access to hormonal contraceptives PT April 2024 For nearly a decade, pharmacists in select jurisdictions have been able to prescribe hormonal contraceptives, and nearly every year, more states pass legislation granting pharmacists this authority. Olivia C. Welter, PharmD
April 7 Practice & Trends Naloxone Study shows significant drop in prescription naloxone pricing PT April 2024 More than 112,000 Americans died as a result of opioid overdoses in 2023, a sobering reminder that the opioid crisis is far from over. Naloxone has proven to be a powerful tool in the ongoing effort to save lives, but its cost has been prohibitive for some. Elizabeth Briand
April 7 Bulletin Today Bulletin Today News Roundup PT April 2024 FDA warns patients not to use smartwatches or smart rings to measure blood glucose levels. Survey looks at characteristics of young adults who use e-cigarettes. CDC: Older adults should get another COVID-19 dose this spring. BP improves with patients taking GLP-1, says study. Low-dose aspirin during pregnancy appears to have no effect on child’s neurodevelopment. Age-related risk of serious falls increases with opioid use. Pennsylvania pharmacists can now bill Medicaid for pharmacy services.
April 7 Today's Perspective Today's Perspective Pharmacists play an important role in caring for transgender patients PT April 2024 There is a growing need for pharmacists to provide care for transgender patients. Kristin Wiisanen, PharmD, FAPhA, FCCP, Pharmacy Today editor in chief
April 7 Association Perspective Association Perspective The prescription for America’s mental health care shortage PT April 2024 Last year, the Commonwealth Fund published an eye-opening report about the significant shortage of behavioral health care providers of all types. Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, Executive vice president and CEO of APhA
April 7 Drugs & Diseases COVID-19 Antivirals Get ready: COVID-19 therapeutics transition to the commercial market PT April 2024 As pandemic uncertainty dissipates, COVID-19 therapeutics are transitioning from U.S. government- procured sources to the commercial market. Clarissa Chan, PharmD
April 7 Drugs & Diseases Opioid Use Disorder Barriers still present for OUD medications even after passage of MAT Act PT April 2024 Even after passage of the Mainstreaming Addiction Treatment (MAT) Act in late 2023, patients still face difficulty gaining access to buprenorphine—the gold standard for treating patients with OUD. Parth Patel, PharmD
April 7 Drugs & Diseases Gabapentin Use of gabapentin in U.S. shows no sign of slowing PT April 2024 Gabapenti.noid use has continued to climb in the United States, despite a lack of strong evidence for its effectiveness in pain management and other uses, according to a recent study published in the January 2024 issue of the Annals of Family Medicine. Elizabeth Briand
April 7 Drugs & Diseases On The Shelf Prebiotics: A gut check PT April 2024 Prebiotic dietary supplements boast that they promote digestive health, reduce inflammation, increase energy and drive, and may help with appetite control. All this and they're also vegan, gluten-free, sugar-free, and keto-friendly. What are prebiotics, anyway? Mickie Cathers
April 7 Drugs & Diseases OTCs Today Muscle aches and pain PT April 2024 Everyone experiences muscle pain (myalgia) at some point in their lives, whether due to overexertion, injury, or disease. Fortunately, numerous options, including 1·est, massage, and medications, are available to relieve the pain. Mary Warner
April 7 Health Systems Trending Topics in Health-System Pharmacy Inpatient Insights PT April 2024 Trending Topics in Health-System Pharmacy
April 7 Health Systems Acute Care Study reveals impact of acute care pharmacists’ role in U.S. PT April 2024 Pharmacists play a critical role within the broad spectrum of multidisciplinary teams in inpatient care environments. Aiya Almogaber, PharmD
April 7 Health Systems Respiratory Distress Experts issue changes in ARDS treatment recommendations PT April 2024 Since the COVID-19 pandemic, the world has seen the extent of harm caused by lung disease and infection. Ariel L. Clark
April 7 Health Systems Neurology Pharmacists improve access to medications in neurology clinic PT April 2024 The last 10 to 15 years have seen approvals of many new specialty and biologic drugs for neurological conditions. Sonya Collins
April 7 Health Systems Heart Failure Pharmacist-led HF clinic optimizes therapy and improves outcomes PT April 2024 Chiefly managed by pharmacotherapy, heart failure with reduced ejection fraction (HFrEF) includes pharmacists on the health care team playing an increasingly pivotal role in optimizing therapy for patients. Corey Diamond, PharmD
April 7 CPE CPE New therapeutic agents marketed in 2023: Part 1 PT April 2024 FDA approved 55 new drugs in 2023. Twenty-eight (51%) of these new drugs received orphan drug designation because they are used in the treatment of patients with rare diseases. Five new therapeutic agents are considered in this review, the first in a two-part series of articles on new therapeutic agents approved in 2023: bexagliflozin (Brenzavvy-TheracosBio ), sotagliflozin (lnpefa- Lexicon), zavegepant hydrochloride (Zavzpret- Pfizer)/ lecanemab-irmb (Leqembi-Eisai; Biogen), and fezolinetant (Veozah-Astellas). Daniel A. Hussar, PhD
April 7 Crossword Challenge Crossword Challenge Crossword Challenge: Test your knowledge! PT April 2024 Crossword Challenge